BidaskClub Downgrades Sientra (NASDAQ:SIEN) to Sell

BidaskClub cut shares of Sientra (NASDAQ:SIEN) from a hold rating to a sell rating in a research note published on Tuesday, November 13th.

SIEN has been the subject of a number of other reports. Zacks Investment Research cut Sientra from a hold rating to a sell rating in a research report on Thursday, October 4th. Canaccord Genuity increased their price objective on Sientra from $19.00 to $25.00 and gave the stock a buy rating in a research report on Wednesday, August 8th. Stephens reaffirmed a buy rating and set a $30.00 price objective on shares of Sientra in a research report on Thursday, August 9th. Stifel Nicolaus increased their price objective on Sientra from $21.00 to $25.00 and gave the stock a buy rating in a research report on Wednesday, August 8th. Finally, Dougherty & Co initiated coverage on Sientra in a research note on Thursday, August 30th. They set a buy rating and a $31.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Sientra currently has a consensus rating of Buy and an average price target of $22.50.

Shares of NASDAQ:SIEN traded up $0.51 on Tuesday, hitting $17.80. 857,423 shares of the company’s stock were exchanged, compared to its average volume of 403,074. The stock has a market cap of $486.19 million, a P/E ratio of -6.31 and a beta of -0.42. Sientra has a 1-year low of $8.79 and a 1-year high of $26.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77.



Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.05). The business had revenue of $16.90 million for the quarter, compared to analyst estimates of $16.66 million. Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. The company’s revenue was up 72.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.74) earnings per share. On average, equities research analysts predict that Sientra will post -3.05 EPS for the current year.

In other news, Director Timothy Haines sold 89,651 shares of the firm’s stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $21.56, for a total transaction of $1,932,875.56. Following the sale, the director now owns 37,662 shares in the company, valued at $811,992.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 31.00% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of SIEN. Vanguard Group Inc. boosted its holdings in Sientra by 1.4% during the third quarter. Vanguard Group Inc. now owns 1,017,312 shares of the medical instruments supplier’s stock valued at $24,293,000 after acquiring an additional 14,422 shares during the period. Teachers Advisors LLC raised its position in shares of Sientra by 29.1% during the third quarter. Teachers Advisors LLC now owns 47,673 shares of the medical instruments supplier’s stock valued at $1,138,000 after buying an additional 10,732 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Sientra by 41.5% during the third quarter. AQR Capital Management LLC now owns 19,345 shares of the medical instruments supplier’s stock valued at $462,000 after buying an additional 5,675 shares during the last quarter. MetLife Investment Advisors LLC raised its position in shares of Sientra by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 17,996 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 6,397 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Sientra during the third quarter valued at about $3,767,000. Hedge funds and other institutional investors own 87.01% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Featured Article: What is a Tariff?

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply